We are live on ! Find out more
TWST icon

Twist Bioscience

163.29 USD
+11.24
7.39%
At close Updated Oct 9, 1:33 PM EDT
1 day
7.39%
5 days
-15.59%
1 month
30.09%
3 months
74.32%
6 months
234.34%
Year to date
404.14%
1 year
412.04%
5 years
61.45%
10 years
1,066.36%
 

About: Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Employees: 979

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 37%
Neutral 63%
Negative 0%
Positive
ETF Trends
9 days ago
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
The Top HealthTech Questions Landing on Our Desks
Neutral
Benzinga
14 days ago
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Neutral
InvestorPlace
16 days ago
3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip
3 Analysts, 3 Trades to Make Today
Positive
The Motley Fool
20 days ago
Why Twist Bioscience Stock Skyrocketed This Week
The biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
Why Twist Bioscience Stock Skyrocketed This Week
Positive
Benzinga
23 days ago
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Positive
Benzinga
23 days ago
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday.
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
Neutral
Business Wire
23 days ago
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan.
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Neutral
ETF Trends
1 month ago
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
AI & Robotics in 2026: 16 Recent Developments for Investors
Neutral
Business Wire
1 month ago
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Positive
Seeking Alpha
1 month ago
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Price charts implemented using Lightweight Charts™